WuXi Biologics Stock

Market capitalization is the stock price multiplied by the number of shares issued.

WuXi Biologics

Enterprise value (EV) is a measure of the value of a company regardless of its financing. It is calculated as follows:
EV = market capitalization - cash + debt.

Enterprise Value metric explained

WuXi Biologics

The P/E ratio or price/earnings ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the stock price to earnings per share.

WuXi Biologics

If you divide the enterprise value by the revenue of the last 12 months, you obtain an important metric for assessing the valuation of companies - even if they are not yet making a profit.

WuXi Biologics

The KUV or price/sales ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the stock price to sales per share.

WuXi Biologics

The P/B ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the stock price to the book value per share.

WuXi Biologics

Sales growth TTM (Trailing Twelve Months) compares the sales of the last 12 months with the sales of the previous 12 months.

WuXi Biologics

Revenue TTM (Trailing Twelve Months) represents the sum of all revenues of a company for its products, services or other items within the last 12 months.

WuXi Biologics

EBIT or the operating result represents the profit or loss after deducting direct costs (cost of sales), sales, marketing, administrative, research and development costs and depreciation and amortization.

WuXi Biologics

EPS TTM (Trailing Twelve Months) or earnings per share represents the profit per share over the last 12 months. The company's net profit is divided by the number of shares.

WuXi Biologics

Price/earnings ratio based on the expected net earnings per share for the financial year ending at Dec 31 2025.

WuXi Biologics

Ratio of market capitalization to sales on the basis of expected sales for the financial year ending at Dec 31 2025

WuXi Biologics

Ratio of enterprise value to sales based on estimated sales for the financial year ending at Dec 31 2025

WuXi Biologics